OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.
Also called NCT07576257
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 110 participants
- Registry
-
NCT07576257
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07576257. Randomized; no masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)
- Acronym
- OPRA-HF Extens
- Condition
- Heart Failure
- Intervention (Drug)
- potassium binder
- Lead sponsor
- Sahlgrenska University Hospital
Record details
- Record id
cardio:ct-nct07576257- Content hash
d4ba20e3761375fabdefd5cb05f163cfca615e6c6bbacf0c82c3d4dc45c96655